This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Monday, February 17, 2014
Caffeinated and decaffeinated coffee associated with lower risk of type 2 diabetes
Higher consumption of coffee is associated with lower risk of type 2 diabetes, according to research published in the February issue of Diabetes Care.
Consuming coffee has been shown to have beneficial effects on everything from weight gain to liver disease, including the prevention of hepatic fibrosis in chronic hepatitis C and NAFLD, as well as lowering the risk for hepatocellular carcinoma HCC.
A systematic review published in this months issue of Diabetes Care suggests caffeinated and decaffeinated coffee also reduced the risk of type 2 diabetes, a summary of data is provided by HealthDay News, below.
To read more about the beneficial effects of coffee on liver disease, click here.
Higher consumption of coffee is associated with lower risk of type 2 diabetes, according to research published in the February issue of Diabetes Care.
MONDAY, Feb. 17, 2014 (HealthDay News) -- Higher consumption of coffee is associated with lower risk of type 2 diabetes, according to research published in the February issue of Diabetes Care.
Ming Ding, of the Harvard School of Public Health in Boston, and colleagues conducted a systematic review of the literature and performed a meta-analysis of 28 prospective cohort or nested case-control studies. The authors sought to assess the effect of coffee consumption on risk of type 2 diabetes.
The researchers found that, compared with no coffee or rare consumption of coffee, the relative risk (RR) for type 2 diabetes was 0.92 (95 percent confidence interval [CI], 0.90 to 0.94) for one cup per day; 0.85 (95 percent CI, 0.82 to 0.88) for two cups per day; 0.79 (95 percent CI, 0.75 to 0.83) for three cups per day; 0.75 (95 percent CI, 0.71 to 0.80) for four cups per day; 0.71 (95 percent CI, 0.65 to 0.76) for five cups per day; and 0.67 (95 percent CI, 0.61 to 0.74) for six cups per day.
No significant difference was found between the reduced risk of diabetes associated with a one cup per day increase for caffeinated coffee (RR, 0.91; 95 percent CI, 0.89 to 0.94) versus decaffeinated coffee (RR, 0.94; 95 percent CI, 0.91 to 0.98) (P for difference = 0.17).
"Coffee consumption was inversely associated with the risk of type 2 diabetes in a dose-response manner," the authors write. "Both caffeinated and decaffeinated coffee was associated with reduced diabetes risk."
Abstract
Full Text (subscription or payment may be required)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment